#BEGIN_DRUGCARD DB04363

# AHFS_Codes:
Not Available

# ATC_Codes:
Not Available

# Absorption:
Not Available

# Biotransformation:
Not Available

# Brand_Mixtures:
Not Available

# Brand_Names:
Not Available

# CAS_Registry_Number:
Not Available

# ChEBI_ID:
Not Available

# Chemical_Formula:
C33H37N4O6

# Chemical_IUPAC_Name:
3-[(2Z)-2-{[4-(2-carboxyethyl)-5-{[(2Z)-3-ethyl-4-methyl-5-oxo-2,5-dihydro-1H-pyrrol-2-ylidene]methyl}-3-methylpyrrol-2-yl]methylidene}-5-{[(2E)-3-ethyl-4-methyl-5-oxo-2,5-dihydro-1H-pyrrol-2-ylidene]methyl}-3-methyl-2H-pyrrol-4-yl]propanoic acid

# Chemical_Structure:
Not Available

# Creation_Date:
2005-06-13 07:24:05 -0600

# DPD_Drug_ID_Number:
Not Available

# Description:
Not Available

# Dosage_Forms:
Not Available

# Drug_Category:
Not Available

# Drug_Interactions:
Not Available

# Drug_Reference:
Not Available

# Drug_Type:
Experimental
Small Molecule

# Experimental_Caco2_Permeability:
Not Available

# Experimental_LogP_Hydrophobicity:
Not Available

# Experimental_Logs:
Not Available

# Experimental_Water_Solubility:
Not Available

# Food_Interactions:
Not Available

# GenBank_ID:
Not Available

# Generic_Name:
Mesobiliverdin Iv Alpha

# HET_ID:
MBV

# Half_Life:
Not Available

# InChI_Identifier:
Not Available

# InChI_Key:
Not Available

# Indication:
Not Available

# KEGG_Compound_ID:
Not Available

# KEGG_Drug_ID:
Not Available

# LIMS_Drug_ID:
4363

# Mechanism_Of_Action:
Not Available

# Melting_Point:
Not Available

# Molecular_Weight_Avg:
585.6701

# Molecular_Weight_Mono:
585.271309936

# Organisms_Affected:
Not Available

# PDB_Experimental_ID:
1HE3

# PDB_Homology_ID:
Not Available

# PDRhealth_Link:
Not Available

# Pathways:
Not Available

# PharmGKB_ID:
Not Available

# Pharmacology:
Not Available

# Predicted_LogP_Hydrophobicity:
3.8

# Predicted_LogS:
-4.4

# Predicted_Water_Solubility:
2.39e-02 g/l

# Primary_Accession_No:
DB04363

# Protein_Binding:
Not Available

# PubChem_Compound_ID:
46936957

# PubChem_Substance_ID:
46508213

# RxList_Link:
Not Available

# Salts:
Not Available

# Secondary_Accession_No:
EXPT02129

# Smiles_String_canonical:
Not Available

# Smiles_String_isomeric:
CCC1=C(C)C(=O)N\C1=C\C1=N\C(=C/c2nc(\C=C3/NC(=O)C(C)=C3CC)c(CCC(O)=O)c2C)\C(C)=C1CCC(O)=O

# State:
solid

# Structure:
1

# SwissProt_ID:
Not Available

# SwissProt_Name:
Not Available

# Synonyms:
Not Available

# Synthesis_Reference:
Not Available

# Toxicity:
Not Available

# Update_Date:
2013-02-08 16:23:15 -0700

# Wikipedia_Link:
Not Available

# pKa_Isoelectric_Point:
Not Available

# Drug_Target_1_Cellular_Location:
Cytoplasm (Potential)

# Drug_Target_1_Chromosome_Location:
Not Available

# Drug_Target_1_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_1_Essentiality:
Non-Essential

# Drug_Target_1_GenAtlas_ID:
BLVRB

# Drug_Target_1_GenBank_ID_Gene:
D26308

# Drug_Target_1_GenBank_ID_Protein:
1384068

# Drug_Target_1_GeneCard_ID:
BLVRB

# Drug_Target_1_Gene_Name:
BLVRB

# Drug_Target_1_Gene_Sequence:
>621 bp
ATGGCCGTCAAGAAGATCGCGATCTTCGGCGCCACTGGCCAGACCGGGCTCACCACCCTG
GCGCAGGCGGTGCAAGCAGGTTACGAAGTGACAGTGCTGGTGCGGGACTCCTCCAGGCTG
CCATCAGAGGGGCCCCGGCCGGCCCACGTGGTAGTGGGAGATGTTCTGCAGGCAGCCGAT
GTGGACAAGACCGTGGCTGGGCAGGACGCTGTCATCGTGCTGCTGGGCACCCGCAATGAC
CTCAGTCCCACGACAGTGATGTCCGAGGGCGCCCGGAACATTGTGGCAGCCATGAAGGCT
CATGGTGTGGACAAGGTCGTGGCCTGCACCTCGGCTTTCCTGCTCTGGGACCCTACCAAG
GTGCCCCCACGACTGCAGGCTGTGACTGATGACCACATCCGGATGCACAAGGTGCTGCGG
GAATCAGGCCTGAAGTACGTGGCTGTGATGCCGCCACACATAGGAGACCAGCCACTAACT
GGGGCGTACACAGTGACCCTGGATGGACGAGGGCCCTCAAGGGTCATCTCCAAACATGAC
CTGGGCCATTTCATGCTGCGCTGCCTCACCACCGATGAGTACGACGGACACAGCACCTAC
CCCTCCCACCAGTACCAGTAG

# Drug_Target_1_General_Function:
Cell wall/membrane/envelope biogenesis

# Drug_Target_1_General_References:
11224564	Pereira PJ, Macedo-Ribeiro S, Parraga A, Perez-Luque R, Cunningham O, Darcy K, Mantle TJ, Coll M: Structure of human biliverdin IXbeta reductase, an early fetal bilirubin IXbeta producing enzyme. Nat Struct Biol. 2001 Mar;8(3):215-20.
1286669	Hochstrasser DF, Frutiger S, Paquet N, Bairoch A, Ravier F, Pasquali C, Sanchez JC, Tissot JD, Bjellqvist B, Vargas R, et al.: Human liver protein map: a reference database established by microsequencing and gel comparison. Electrophoresis. 1992 Dec;13(12):992-1001.
7929092	Yamaguchi T, Komoda Y, Nakajima H: Biliverdin-IX alpha reductase and biliverdin-IX beta reductase from human liver. Purification and characterization. J Biol Chem. 1994 Sep 30;269(39):24343-8.
8117274	Chikuba K, Yubisui T, Shirabe K, Takeshita M: Cloning and nucleotide sequence of a cDNA of the human erythrocyte NADPH-flavin reductase. Biochem Biophys Res Commun. 1994 Feb 15;198(3):1170-6.
8280170	Yamaguchi T, Komuro A, Nakano Y, Tomita M, Nakajima H: Complete amino acid sequence of biliverdin-IX beta reductase from human liver. Biochem Biophys Res Commun. 1993 Dec 30;197(3):1518-23.
8313871	Golaz O, Hughes GJ, Frutiger S, Paquet N, Bairoch A, Pasquali C, Sanchez JC, Tissot JD, Appel RD, Walzer C, et al.: Plasma and red blood cell protein maps: update 1993. Electrophoresis. 1993 Nov;14(11):1223-31.
8687377	Shalloe F, Elliott G, Ennis O, Mantle TJ: Evidence that biliverdin-IX beta reductase and flavin reductase are identical. Biochem J. 1996 Jun 1;316 ( Pt 2):385-7.
8799475	Komuro A, Tobe T, Hashimoto K, Nakano Y, Yamaguchi T, Nakajima H, Tomita M: Molecular cloning and expression of human liver biliverdin-IX beta reductase. Biol Pharm Bull. 1996 Jun;19(6):796-804.

# Drug_Target_1_HGNC_ID:
HGNC:1063

# Drug_Target_1_HPRD_ID:
02967

# Drug_Target_1_ID:
654

# Drug_Target_1_Locus:
19q13.1-q13.2

# Drug_Target_1_Molecular_Weight:
21988

# Drug_Target_1_Name:
Flavin reductase

# Drug_Target_1_Number_of_Residues:
205

# Drug_Target_1_PDB_ID:
1HE5

# Drug_Target_1_Pathway:
Not Available

# Drug_Target_1_Pfam_Domain_Function:
PF01370	Epimerase

# Drug_Target_1_Protein_Sequence:
>Flavin reductase
AVKKIAIFGATGQTGLTTLAQAVQAGYEVTVLVRDSSRLPSEGPRPAHVVVGDVLQAADV
DKTVAGQDAVIVLLGTRNDLSPTTVMSEGARNIVAAMKAHGVDKVVACTSAFLLWDPTKV
PPRLQAVTDDHIRMHKVLRESGLKYVAVMPPHIGDQPLTGAYTVTLDGRGPSRVISKHDL
GHFMLRCLTTDEYDGHSTYPSHQYQ

# Drug_Target_1_Reaction:
bilirubin + NAD(P)+ = biliverdin + NAD(P)H + H+

# Drug_Target_1_Signals:
None

# Drug_Target_1_Specific_Function:
Catalyzes electron transfer from reduced pyridine nucleotides to flavins as well as methylene blue, pyrroloquinoline quinone, riboflavin, or methemoglobin. Possible role in protecting cells from oxidative damage or in regulating iron metabolism. In the liver, converts biliverdin to bilirubin

# Drug_Target_1_SwissProt_ID:
P30043

# Drug_Target_1_SwissProt_Name:
BLVRB_HUMAN

# Drug_Target_1_Synonyms:
BVR-B
Biliverdin reductase B
Biliverdin-IX beta-reductase
EC 1.3.1.24
EC 1.5.1.30
FLR
FR
GHBP
Green heme-binding protein
NADPH-dependent diaphorase
NADPH-flavin reductase

# Drug_Target_1_Theoretical_pI:
7.76

# Drug_Target_1_Transmembrane_Regions:
None

#END_DRUGCARD DB04363
